For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Biogen Ma Inc.

USPTO Granted Patents = 253

CIPO Patents = 28

EPO Patents = 139

Trademarks = 45

Forward Citations = 937

Loading Chart...

Loading Chart...

407 inventors (with patents filed for the assignee):

Gnanasambandam Kumaravel (33 out of 60 patents)

Bin Ma (33 out of 37 patents)

Kevin Guckian (29 out of 39 patents)

4. Brian T Hopkins (22 out of 32 patents)

5. Zhili Xin (20 out of 43 patents)

6. Lei Zhang (17 out of 21 patents)

7. Sha Mi (16 out of 34 patents)

8. Timothy Raymond Chan (15 out of 18 patents)

9. Meena Subramanyam (14 out of 16 patents)

10. Jermaine Thomas (14 out of 21 patents)

11. Tatiana Plavina (13 out of 13 patents)

12. Edward Yin-Shiang Lin (13 out of 22 patents)

13. Tracy J Jenkins (13 out of 19 patents)

14. Arthur G Taveras (13 out of 72 patents)

15. Joseph P Lyssikatos (12 out of 139 patents)

Core Competencies:

Glycogen Synthase Kinase 3 Inhibitors

Hypercholesterolemia Treatment

Neurofilament Protein

Bruton's Tyrosine Kinase Inhibitors

Anti-VLA-4 Therapy

Oligonucleotide Synthesis

Cation-Exchange Chromatography

Alzheimer's Disease Treatment

Tau Expression Modulation

Cerebral Hemorrhage Prevention

Autoimmune Disorder Treatments

JC Virus Antibodies

253 patents: Sort by Forward Citations

1. 12522595 - Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2026-01-13),

2. 12516280 - Cross-scale modeling of bioreactor cultures using raman spectroscopy (2026-01-06),

3. 12486289 - Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof (2025-12-02),

4. 12472171 - Methods for treating hypercholesterolemia (2025-11-18),

5. 12467929 - METHODS OF DETECTING UBE3A PROTEIN (2025-11-11),

6. 12441980 - Methods for overcoming glutamine deprivation during mammalian cell culture (2025-10-14),

7. 12429487 - Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis (2025-09-30),

8. 12421224 - Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors (2025-09-23),

9. 12404263 - ASK1 inhibiting agents (2025-09-02),

10. 12392784 - Method of assessing risk of PML (2025-08-19),

11. 12391697 - Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase (2025-08-19),

12. 12385925 - Anti-VLA-4 related assays (2025-08-12),

13. 12378276 - Convergent liquid phase syntheses of oligonucleotides (2025-08-05),

14. 12372470 - Use of raman spectroscopy to monitor culture medium (2025-07-29),

15. 12357569 - Infusing drug solution directly into brain fluid (2025-07-15),

Biogen is a global biotechnology company that focuses on the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. With a mission to transform the lives of patients and provide hope, Biogen strives to advance scientific knowledge and create innovative treatment options. Their dedication to breakthrough research, cutting-edge technology, and collaboration with healthcare professionals contributes to the improvement of patient outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

253 Patents

#13 in Cambridge, MA

#102 in Massachusetts

#1,626 in US

#3,340 in the World

Cambridge, MA, United States of America

Biogen Ma Inc.

Forward Citations = 937

407 inventors:

Gnanasambandam Kumaravel (33 out of 60 patents)

Bin Ma (33 out of 37 patents)

Kevin Guckian (29 out of 39 patents)

4. Brian T Hopkins (22 out of 32 patents)

5. Zhili Xin (20 out of 43 patents)

Please report any incorrect information to support@idiyas.com

Loading…